{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:05:09Z","timestamp":1789578309704,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006364","name":"French National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.euo.2026.04.009","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T04:59:38Z","timestamp":1781240378000},"page":"997-1004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Study Protocol of OLIGOPELVIS 2\u2013GETUG P12: A Randomized Phase 3 Study Comparing Intermittent Androgen-deprivation Therapy with or Without Salvage High-dose Intensity-modulated Radiotherapy to Oligorecurrent Pelvic and Para-aortic Lymph Nodes in Patients with Biochemically Relapsing Prostate Cancer"],"prefix":"10.1016","volume":"9","author":[{"given":"Quentin","family":"Josset","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Blanc-Lapierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9goire","family":"Pigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lysian","family":"Cartier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ronchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Bera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hasbini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Schipman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Khalifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Quivrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Schick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Mallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Laude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clotilde","family":"Morand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Loos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loig","family":"Vaugier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Mesgouez-Nebout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2094-1708","authenticated-orcid":false,"given":"St\u00e9phane","family":"Supiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.04.009_b0005","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/pros.22750","article-title":"Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer","volume":"74","author":"Ost","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2026.04.009_b0010","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41585-020-0310-3","article-title":"Harnessing the potential of multimodal radiotherapy in prostate cancer","volume":"17","author":"Philippou","year":"2020","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2026.04.009_b0015","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.3390\/cancers15061898","article-title":"Comparison of hormone-sensitive oligorecurrent prostate cancer patients based on routine use of choline and\/or PSMA PET\/CT to guide metastasis-directed therapy","volume":"15","author":"Metz","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2026.04.009_b0020","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1470-2045(16)00107-8","article-title":"Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01\u201303 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial","volume":"17","author":"Duchesne","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.04.009_b0025","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.04.009_b0030","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.eururo.2023.10.012","article-title":"The efficacy and safety of metastasis-directed therapy in patients with prostate cancer: A systematic review and meta-analysis of prospective studies","volume":"85","author":"Miszczyk","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.04.009_b0035","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND Phase 2 randomized clinical trial","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2026.04.009_b0040","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.eururo.2014.02.011","article-title":"Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years","volume":"67","author":"Suardi","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.04.009_b0045","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.3109\/0284186X.2013.764010","article-title":"Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and\/or distant metastases","volume":"52","author":"Schick","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.euo.2026.04.009_b0050","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1186\/s12885-015-1579-0","article-title":"OLIGOPELVIS - GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer","volume":"15","author":"Supiot","year":"2015","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.euo.2026.04.009_bib121","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ijrobp.2018.12.020","article-title":"Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07)","volume":"103","author":"Vaugier","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2026.04.009_b0055","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2021.06.010","article-title":"OLIGOPELVIS GETUG P07, a multicenter Phase II trial of combined high-dose salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses in prostate cancer","volume":"80","author":"Supiot","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.04.009_b0060","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.eururo.2024.02.013","article-title":"Long-term outcomes and patterns of relapse following high-dose elective salvage radiotherapy and hormone therapy in oligorecurrent pelvic nodes in prostate cancer: OLIGOPELVIS (GETUG-P07)","volume":"87","author":"Vaugier","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.04.009_b0065","doi-asserted-by":"crossref","unstructured":"Tilki D, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol 2024:164\u201382 Update: EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of relapsing and metastatic prostate cancer. Eur Urol 2024;86:164\u201382.","DOI":"10.1016\/j.eururo.2024.04.010"},{"key":"10.1016\/j.euo.2026.04.009_b0070","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate Cancer-2024 update. Part I: Screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.04.009_b0075","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.radonc.2022.06.014","article-title":"Cost-effectiveness of hypofractionated versus conventional radiotherapy in patients with intermediate-risk prostate cancer: an ancillary study of the PROstate fractionated irradiation trial - PROFIT","volume":"173","author":"Zhou","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.euo.2026.04.009_b0080","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1001\/jamadermatol.2022.4556","article-title":"Cost-effectiveness of response-adapted de-escalation of immunotherapy in advanced melanoma","volume":"158","author":"Cartun","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.euo.2026.04.009_b0085","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.ctrv.2015.10.005","article-title":"Definition of lymph node areas for radiotherapy of prostate cancer: a critical literature review by the French Genito-Urinary Group and the French Association of Urology (GETUG-AFU)","volume":"41","author":"Sargos","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.euo.2026.04.009_b0090","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ijrobp.2009.02.006","article-title":"Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer","volume":"76","author":"Michalski","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2026.04.009_b0095","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ijrobp.2008.08.002","article-title":"RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer","volume":"74","author":"Lawton","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2026.04.009_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2026.111476","article-title":"Cumulative dose analysis following elective pelvis re-irradiation at junction with primary prostate radiotherapy from the OLIGOPELVIS GETUG P07 trial","volume":"219","author":"Vaugier","year":"2026","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.euo.2026.04.009_b0105","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1056\/NEJMoa2510310","article-title":"Improved survival with enzalutamide in biochemically recurrent prostate cancer","volume":"394","author":"Shore","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.04.009_b0110","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.eururo.2025.05.006","volume":"88","author":"Mazzone","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.04.009_b0115","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1470-2045(25)00197-4","article-title":"Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial","volume":"26","author":"Ost","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.04.009_b0120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(25)00658-8","article-title":"Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration","volume":"27","author":"Tang","year":"2026","journal-title":"Lancet Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:45:38Z","timestamp":1789577138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126001136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2588931126001136"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.04.009","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Study Protocol of OLIGOPELVIS 2\u2013GETUG P12: A Randomized Phase 3 Study Comparing Intermittent Androgen-deprivation Therapy with or Without Salvage High-dose Intensity-modulated Radiotherapy to Oligorecurrent Pelvic and Para-aortic Lymph Nodes in Patients with Biochemically Relapsing Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}